Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Income from Continuing Operations (2016 - 2025)

Traws Pharma (TRAW) has disclosed Income from Continuing Operations for 14 consecutive years, with 7368000.0 as the latest value for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 39.6% year-over-year to 7368000.0; the TTM value through Dec 2025 reached 17875000.0, up 87.45%, while the annual FY2025 figure was 17875000.0, 87.45% up from the prior year.
  • Income from Continuing Operations hit 7368000.0 in Q4 2025 for Traws Pharma, down from 4055000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1249000.0 in Q2 2025 and bottomed at 123348000.0 in Q2 2024.
  • Average Income from Continuing Operations over 5 years is 10833500.0, with a median of 4867000.0 recorded in 2021.
  • Year-over-year, Income from Continuing Operations tumbled 2575.66% in 2024 and then soared 98.99% in 2025.
  • Traws Pharma's Income from Continuing Operations stood at 3763000.0 in 2021, then tumbled by 52.38% to 5734000.0 in 2022, then grew by 22.18% to 4462000.0 in 2023, then dropped by 18.29% to 5278000.0 in 2024, then plummeted by 39.6% to 7368000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 7368000.0, 4055000.0, and 1249000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.